Dr. Lunning is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
987400 Nebraska Medical Ctr
Omaha, NE 68198Phone+1 402-552-2000Fax+1 402-552-2512
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Nebraska Medical Center College of MedicineResidency, Internal Medicine, 2006 - 2009
Des Moines University College of Osteopathic MedicineClass of 2006
Certifications & Licensure
IA State License 2008 - 2026
NE State License 2007 - 2026
CO State License 2024 - 2025
KS State License 2024 - 2025
ND State License 2024 - 2025
WY State License 2024 - 2025
NY State License 2010 - 2013- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
- Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma Start of enrollment: 2015 Sep 28
- Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) Start of enrollment: 2016 Jan 06
- Join now to see all
Publications & Presentations
PubMed
- 1193 citationsLisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang
Lancet. 2020-09-19 - 87 citationsReal-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.Caron A Jacobson, Frederick L Locke, Long Ma, Julius Asubonteng, Zhen-Huan Hu
Transplantation and Cellular Therapy. 2022-09-01 - 297 citationsA targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe O. Odejide, Oliver Weigert, Andrew A. Lane, Dan Toscano, Matthew A. Lunning
Blood. 2014-02-27
Journal Articles
- Do You Know TAFRO?James O Armitage, Matthew A Lunning, Blood
Lectures
- Driving Forces in Patient Selection for CAR T-Cell Therapy in Aggressive LymphomaASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019
- Realizing the Promise of Novel Therapeutics in NHL: A MasterClass and Tumor Board on Clinical Decision-Making in FL, MCL, and DLBCL61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Targeting Oncoprotein Translation with Rocaglates in MYC-Driven Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
TG Therapeutics, Inc. Announces Investigator Initiated Trial at the University of Nebraska Medical Center to Study TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory DiffusJanuary 4th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
